SF3B1 and myeloproliferative disorder: MDS/MPN with ring sideroblasts and thrombocytosis have been redefined in the 2022 WHO classification based on SF3B1 mutation and renamed MDS/MPN with SF3B1 mutation and thrombocytosis [107].